Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomised, placebo-controlled trial with a re-treatment extension.
Phase of Trial: Phase II
Latest Information Update: 17 May 2012
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- 17 May 2012 New trial record